MedTrace Logo

Residual Gastric Volume After the Ingestion of Supplements Containing Carbohydrates and Whey Protein

NCT05573854 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-10-10

No results posted yet for this study

Summary

Oral supplements (OS) containing carbohydrates are being used 2h before anesthesia. The addition of a nitrogen source would improve these drinks designed for the abbreviation of preoperative fasting. The gastric emptying of an oral supplement containing whey protein in addition to carbohydrates was investigated. This is a randomized crossover study including six healthy young volunteers who were submitted to abdominal MRI in 3 phases: 1) after a overnight fast, 2) after drank 200 mL of an OS containing whey protein and carbohydrates (no lipids), and 3) 3h after ingestion of the mentioned OS. The gastric residual volume (GRV) will be evaluate by MRI. The overall findings would allow us to conclude whether the GRV, assessed by MRI, in healthy young volunteers after three hours of the ingestion of 200 ml of an oral supplement containing carbohydrates associated with whey proteins is similar to the GRV found after an overnight fast. This pilot study will add important information to allow future randomized trials including an arm with patients undergoing elective surgical procedures with a 3h fasting after the ingestion of an OS containing whey protein and carbohydrates.

Conditions

  • Fasting
  • Gastric Stasis
  • Perioperative Complication
  • Safety Issues

Interventions

DIETARY_SUPPLEMENT

Gastric emptying after an oral supplement containing carbohydrates and whey protein

Ingestion of an oral supplement containing carbohydrates and whey protein

DIETARY_SUPPLEMENT

Overnight Fast

Residual Gastric Volume assessed by MRI after overnight fast (8h)

Sponsors & Collaborators

  • Univag Centro Universitário

    collaborator OTHER

  • Federal University of Mato Grosso

    lead OTHER

Principal Investigators

  • Jose E Aguilar-Nascimento, MD, PhD · Univag Centro Universitário

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-05-30
Completion
2022-05-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05573854 on ClinicalTrials.gov